Stroke survivors get new hope: major trial tests colchicine and ticagrelor to prevent repeat attacks.
NCT ID NCT05476991
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial is testing whether two drugs—colchicine (used for gout) and ticagrelor (a blood thinner)—can prevent future strokes, heart attacks, and other vascular events in people who have already had a stroke. About 2,800 high-risk participants will be enrolled. The goal is to see if adding these drugs to standard care reduces inflammation and clotting, lowering the chance of another event.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Colchicine and ticagrelor
What this could lead to
If successful, this could provide a new way to reduce the risk of another stroke or heart attack in people who have already had a stroke.
What could go wrong
This is a large phase 3 trial, but it is still testing whether these drugs work better than current treatments. There may be side effects like bleeding or stomach issues, and the results may not apply to all stroke patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
URC Lariboisière-Fernand Widal-Saint Louis
RECRUITINGParis, Paris, 75010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact